CL2016002123A1 - Nuevo polisacárido y usos del mismo - Google Patents

Nuevo polisacárido y usos del mismo

Info

Publication number
CL2016002123A1
CL2016002123A1 CL2016002123A CL2016002123A CL2016002123A1 CL 2016002123 A1 CL2016002123 A1 CL 2016002123A1 CL 2016002123 A CL2016002123 A CL 2016002123A CL 2016002123 A CL2016002123 A CL 2016002123A CL 2016002123 A1 CL2016002123 A1 CL 2016002123A1
Authority
CL
Chile
Prior art keywords
new polysaccharide
new
polysaccharide
polisacárido
coli
Prior art date
Application number
CL2016002123A
Other languages
English (en)
Inventor
Michael T Kowarik
Michael L Wetter
Stefan J Kemmler
Micha A Häuptle
Veronica Gambillara
Manuela Mally
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of CL2016002123A1 publication Critical patent/CL2016002123A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0066—Isolation or extraction of proteoglycans from organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>NUEVO POLISACÁRIDO DE E. COLI Y USOS DEL MISMO</p>
CL2016002123A 2014-02-24 2016-08-23 Nuevo polisacárido y usos del mismo CL2016002123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461943710P 2014-02-24 2014-02-24

Publications (1)

Publication Number Publication Date
CL2016002123A1 true CL2016002123A1 (es) 2018-02-16

Family

ID=52589386

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002123A CL2016002123A1 (es) 2014-02-24 2016-08-23 Nuevo polisacárido y usos del mismo

Country Status (27)

Country Link
US (5) US9700612B2 (es)
EP (1) EP3110441B1 (es)
JP (2) JP6276427B2 (es)
KR (1) KR101855142B1 (es)
CN (1) CN106535927B (es)
AR (1) AR100859A1 (es)
AU (1) AU2015220723C1 (es)
CA (1) CA2940547C (es)
CL (1) CL2016002123A1 (es)
DK (1) DK3110441T3 (es)
EA (1) EA035991B9 (es)
ES (1) ES2978870T3 (es)
FI (1) FI3110441T3 (es)
HR (1) HRP20240847T1 (es)
HU (1) HUE066507T2 (es)
IL (1) IL247344B (es)
LT (1) LT3110441T (es)
MX (1) MX2016011055A (es)
NZ (1) NZ723328A (es)
PH (1) PH12016501671B1 (es)
PL (1) PL3110441T3 (es)
PT (1) PT3110441T (es)
RS (1) RS65631B1 (es)
SG (1) SG11201606889PA (es)
SI (1) SI3110441T1 (es)
TW (1) TWI639439B (es)
WO (1) WO2015124769A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2669420T3 (es) 2013-01-17 2018-05-25 Arsanis Biosciences Gmbh Anticuerpo específico de E.coli MDR
LT3110441T (lt) * 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
EP3294761A4 (en) * 2015-05-13 2019-04-03 University of Washington COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711637D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US20190275135A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against intra-abdominal infections
CN108531439B (zh) * 2018-04-16 2020-04-07 南京工业大学 一种大肠杆菌基因工程菌及其构建方法与应用
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
SG11202110301TA (en) 2019-03-18 2021-10-28 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
JP2022525773A (ja) * 2019-03-18 2022-05-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 大腸菌ｏ抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法
CN110018253A (zh) * 2019-04-15 2019-07-16 艾美卫信生物药业（浙江）有限公司 一种生物制品中游离蛋白含量的高效液相测定方法
CN111855826B (zh) * 2019-04-24 2022-09-16 岛津企业管理（中国）有限公司 破伤风类毒素或白喉类毒素的监测方法
GB201908528D0 (en) * 2019-06-13 2019-07-31 Univ Dundee Rhamnose-polysaccharides
BR112022013720A2 (pt) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc Mutante fimh, composições com o mesmo e seu uso
CN115697396A (zh) 2020-06-18 2023-02-03 葛兰素史克生物有限公司 志贺氏菌-四价（Shigella4V）生物缀合物
WO2021259743A2 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Vaccine
PE20231385A1 (es) * 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
US20230349913A1 (en) * 2020-11-30 2023-11-02 Janssen Pharmaceuticals, Inc. Analytical method for glycogonjugates using a capillary-based immunoassay system
IL303954A (en) 2021-01-12 2023-08-01 Janssen Pharmaceuticals Inc FIMH mutants, their compositions and their use
US20240226260A9 (en) 2021-02-16 2024-07-11 Duke University Vaccine compositions and methods for the treatment and prevention of urinary tract infections
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
KR20240005684A (ko) 2021-04-08 2024-01-12 얀센 파마슈티칼즈, 인코포레이티드 바이오컨쥬게이트 생산 방법
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
US12014256B2 (en) * 2022-01-12 2024-06-18 Dell Products L.P Polysaccharide archival storage
CN114150005B (zh) * 2022-02-09 2022-04-22 广州恩宝生物医药科技有限公司 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗
WO2024123667A1 (en) * 2022-12-05 2024-06-13 Janssen Pharmaceuticals, Inc. Bioconjugate compositions and process for bioconjugate production
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
ES2258214T3 (es) 2002-03-07 2006-08-16 Eidgenossische Technische Hochschule Zurich Sistema y procedimiento para la produccion de proteinas glucosiladas recombinantes en un huesped procariotico.
PL2311972T3 (pl) 2005-05-11 2015-08-31 Eth Zuerich Rekombinowane n-glikozylowane białka z komórek prokariotycznych
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
PL2257307T3 (pl) * 2008-02-20 2018-11-30 Glaxosmithkline Biologicals S.A. Biokoniugaty wytworzone z rekombinowanych n-glikozylowanych białek z komórek prokariotycznych
EP2501406B8 (en) 2009-11-19 2018-01-24 GlaxoSmithKline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
KR20140005892A (ko) 2010-12-10 2014-01-15 머크 샤프 앤드 돔 코포레이션 면역원성 조성물의 진탕-유도된 응집을 완화시키는 신규한 제제
AU2012306345A1 (en) 2011-09-06 2014-03-20 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
WO2014037585A1 (en) 2012-09-10 2014-03-13 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
MX365435B (es) 2012-10-12 2019-06-03 Glaxosmithkline Biologicals Sa Metodos de modificacion de celulas huesped.
JP2016501550A (ja) 2012-12-27 2016-01-21 グリコヴァキシン アーゲー Ｃｒｍ１９７に関する方法及び組成物
ES2669420T3 (es) * 2013-01-17 2018-05-25 Arsanis Biosciences Gmbh Anticuerpo específico de E.coli MDR
CA2926523C (en) 2013-10-11 2023-09-26 Glycovaxyn Ag Methods of host cell modification
US12103962B2 (en) 2014-02-06 2024-10-01 X4 Pharmaceuticals (Austria) GmbH E. coli specific antibodies
LT3110441T (lt) 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
EP4043561A1 (en) 2014-12-30 2022-08-17 GlaxoSmithKline Biologicals SA Compositions and methods for protein glycosylation
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
SG11202110301TA (en) 2019-03-18 2021-10-28 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
JP2022525773A (ja) 2019-03-18 2022-05-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 大腸菌ｏ抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法

Also Published As

Publication number Publication date
US20200129605A1 (en) 2020-04-30
SI3110441T1 (sl) 2024-07-31
PT3110441T (pt) 2024-05-03
TW201615211A (zh) 2016-05-01
NZ723328A (en) 2018-01-26
EA035991B1 (ru) 2020-09-10
US20230364214A1 (en) 2023-11-16
LT3110441T (lt) 2024-04-25
EP3110441B1 (en) 2024-04-03
MX2016011055A (es) 2017-10-24
AU2015220723C1 (en) 2018-04-05
EP3110441A1 (en) 2017-01-04
US20170340718A1 (en) 2017-11-30
SG11201606889PA (en) 2016-09-29
AR100859A1 (es) 2016-11-09
EA201691478A1 (ru) 2017-02-28
JP6276427B2 (ja) 2018-02-07
IL247344A0 (en) 2016-11-30
US20210154286A1 (en) 2021-05-27
HUE066507T2 (hu) 2024-08-28
JP6771499B2 (ja) 2020-10-21
ES2978870T3 (es) 2024-09-23
EA035991B9 (ru) 2020-10-21
JP2017507178A (ja) 2017-03-16
KR20160125494A (ko) 2016-10-31
US11738076B2 (en) 2023-08-29
US9700612B2 (en) 2017-07-11
PH12016501671A1 (en) 2016-10-03
CA2940547A1 (en) 2015-08-27
FI3110441T3 (fi) 2024-05-06
WO2015124769A1 (en) 2015-08-27
CA2940547C (en) 2021-01-05
AU2015220723A1 (en) 2016-09-22
BR112016019341A2 (pt) 2018-01-16
US20150238588A1 (en) 2015-08-27
CN106535927A (zh) 2017-03-22
IL247344B (en) 2020-06-30
PL3110441T3 (pl) 2024-08-05
RS65631B1 (sr) 2024-07-31
AU2015220723B2 (en) 2017-12-14
US10940192B2 (en) 2021-03-09
JP2018087197A (ja) 2018-06-07
KR101855142B1 (ko) 2018-05-08
PH12016501671B1 (en) 2016-10-03
CN106535927B (zh) 2019-09-20
TWI639439B (zh) 2018-11-01
DK3110441T3 (da) 2024-05-06
US10441647B2 (en) 2019-10-15
HRP20240847T1 (hr) 2024-09-27

Similar Documents

Publication Publication Date Title
CL2016002123A1 (es) Nuevo polisacárido y usos del mismo
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016003416A1 (es) Herbicidas de piperidinona
CL2016002731A1 (es) Herbicidas de piridazinona
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
EA201691991A1 (ru) Мультиспецифические антитела
BR112016026001A2 (pt) Composições de biocerâmica e usos biomoduladores das mesmas
BR112017007160A2 (pt) sistemas de catalisador de fosfinimida de titânio e de iminoimidazolidida de titânio com suportes de ativador.
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
ECSP17015977A (es) Terapia de combinacion
TWD171711S (zh) 端子
BR112016024298A2 (pt) compostos de quinoxalina e seus usos.
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
AU363883S (en) Tracking device
CL2015003493S1 (es) Mueble.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
CL2016002608A1 (es) Nuevo activador de suelo que comprende lignosulfonato de amonio, y usos del mismo
IT201600090701A1 (it) Procedimento di sintesi sostenibile del 4-bromotimolo e uso dello stesso come antimicrobico.
FR3030531B1 (fr) Agent epaississant pour systemes aqueux, formulations le contenant et utilisations
UA114708U (uk) Тяговий привід електробуса
UA92941U (uk) Застосування декаметоксину як протимікробного засобу проти бактерій роду bulkholderia